Clinical trial landscape analysis
Every trial in your indication, and why the stopped ones stopped.
Atlas builds a sourced corpus of trials and papers from a disease, a target and a few keywords, then lays out phases, statuses and stated stop reasons, so a landscape takes minutes instead of weeks of registry searches.
- clinical trials in the corpus
- 50
- papers in the corpus
- 421
- phase 3 trials, all still running
- 8
- trials stopped, each with its stated reason
- 15
Step 1 of 4
Describe the question the way you would to a colleague
A disease, a target and a few keywords. Precision mode keeps retrieval on the target instead of the whole disease area.
- Disease
- Non-small cell lung cancer
- Target
- KRAS G12C
- Keywords
- KRAS G12C inhibitor, sotorasib, adagrasib, divarasib, olomorasib, glecirasib
- Precision mode: on
- Targeted trial and paper retrieval, excluding broad disease-only expansion.
Step 2 of 4
Atlas builds the corpus and keeps the rest within reach
Trials come from the registry with their phase, status, sponsor, dates and enrollment. Papers come with their abstracts and an analysis. What is not selected stays as a candidate you can promote.
- In corpus
- Candidates you can promote
Each row is scaled to its own total.
Step 3 of 4
See where the field is, phase by phase
In this landscape, 9 of the 22 phase 1 trials have stopped. None of the 8 phase 3 trials has.
- Active or planned
- Completed
- Stopped (terminated, withdrawn, suspended)
- Other or unknown
Step 4 of 4
Read why trials stopped, in the sponsor's own words
Each stopped trial keeps the reason recorded on the registry. Here, only 1 of 15 stopped for futility.
- Sponsor or business decision8“Business objectives have changed” · “Sponsor decision”
- Low or no enrollment4“Grantor withdrew support due to slow accrual”
- Futility1“Futility”
- Administrative1
- Merged into another study1
Why it matters: a stopped trial is not a failed molecule. Separating business stops from efficacy stops changes how you read a competitor’s pipeline.
Example output
The 8 phase 3 trials in this landscape
Together they plan to enroll 5,135 patients. Sponsors are shown as registered.
| Trial | Regimen | Sponsor | Enrollment | Status | Start |
|---|---|---|---|---|---|
| NCT06119581 | Olomorasib + pembrolizumab, with or without chemotherapyFirst line (SUNRAY-01) | Eli Lilly and Company | 1,264 | Recruiting | Dec 2023 |
| NCT05920356 | Sotorasib + platinum doubletFirst line, PD-L1 negative (CodeBreaK 202) | Amgen | 750 | Recruiting | Nov 2023 |
| NCT06890598 | Olomorasib + standard of careResected or unresectable disease (SUNRAY-02) | Eli Lilly and Companywith AstraZeneca | 700 | Recruiting | Mar 2025 |
| NCT06875310 | Adagrasib + pembrolizumab + chemotherapyFirst line (KRYSTAL-4) | Mirati Therapeutics Inc. | 630 | Recruiting | Apr 2025 |
| NCT06793215 | Divarasib + pembrolizumabFirst line | Hoffmann-La Rochewith Chugai Pharmaceutical | 600 | Recruiting | Oct 2025 |
| NCT04685135 | Adagrasib vs docetaxelPreviously treated | Mirati Therapeutics Inc. | 453 | Active, not recruiting | Feb 2021 |
| NCT07541170 | Divarasib vs investigator's choiceResected stage II–III, adjuvant | Hoffmann-La Roche | 400 | Recruiting | Sep 2026 |
| NCT06497556 | Divarasib vs sotorasib or adagrasibPreviously treated, head-to-head | Hoffmann-La Rochewith Chugai Pharmaceutical | 338 | Active, not recruiting | Sep 2024 |
Run this on your own indication
We set up a project on your disease and target with you and walk through the landscape together.
Request a demoSource: ClinicalTrials.gov records as ingested by Atlas for the example project, built on 10 Oct 2026. Enrollment is the registered target or actual count. Registry data changes; figures describe the project on that date.